CurrentEndo
Get Weekly

CurrentEndo coverage · page 27 of 55

Diabetes, Obesity and Metabolism

Briefs 1,041–1,080 of 2,200 CurrentEndo has covered from this journal, newest publication first

Latest from Diabetes, Obesity and Metabolism

All coverage, newest first

  1. Diabetes Obes Metab

    Get ahead of the disease: Islet cell autoimmunity and preclinical phase of type 1 diabetes in general population of 1–9 year‐old children in the north‐eastern region of Poland —A summary of the first 18 months of the study

    Cohort studyT1D

  2. Diabetes Obes Metab

    Obesity drives the link between liver fat and depression: Cross‐sectional and prospective investigations

    Cross-sectional studyObesity

  3. Diabetes Obes Metab

    Risk factors for development of diabetic foot ulcer disease in two large contemporary UK cohorts

    Cohort studyComplications

  4. Diabetes Obes Metab

    Real‐world insights into incretin‐based therapy: Associations between changes in taste perception and appetite regulation in individuals with obesity and overweight: A cross‐sectional study

    Cross-sectional studyObesity

  5. Diabetes Obes Metab

    Worldwide burden of metabolic risk‐related cardiovascular disease from 1990 to 2021, with projections to 2050: A systematic analysis for the Global Burden of Disease Study 2021

    Cohort study

  6. Diabetes Obes Metab

    Efficacy and safety of danuglipron ( PF ‐06882961) in adults with obesity: A randomized, placebo‐controlled, dose‐ranging phase 2b study

    Randomized controlled trialObesity

  7. Diabetes Obes Metab

    Mediterranean diet vs. the Australian guide to healthy eating ( AGHE ) on body composition and glucose metabolism: A randomized controlled trial

    Randomized controlled trialObesity

  8. Diabetes Obes Metab

    Interaction between dietary omega‐3 polyunsaturated fatty acids, obesity and gut microbiota in preclinical models: A systematic review of randomized controlled trials

    Meta-analysisObesity

  9. Diabetes Obes Metab

    Predictors of diabetic ketoacidosis in patients with insulin‐deficient diabetes phenotype initiating SGLT2 inhibitors

    Cohort study

  10. Diabetes Obes Metab

    Type 2 diabetes and depression via microvascular dysfunction, neurodegeneration, inflammation, advanced glycation end products ( AGEs ), and arterial stiffness

    Cohort studyComplications

  11. Diabetes Obes Metab

    Gestational diabetes risk associated with early pregnancy blood pressure characteristics and trajectories: A Chinese prospective cohort study

    Cohort studyDiabetes in pregnancy

  12. Diabetes Obes Metab

    Indirect comparative efficacy and safety of tirzepatide 10 and 15 mg versus semaglutide 2.4 mg for the management of obesity and overweight in patients with type 2 diabetes

    Randomized controlled trialObesity

  13. Diabetes Obes Metab

    Socio‐demographic and clinical factors associated with the receipt of anti‐obesity medication prescriptions and metabolic and bariatric surgery among eligible all of Us participants

    Cross-sectional studyObesity

  14. Diabetes Obes Metab

    Efficacy and safety of a tubeless open‐source hybrid automated insulin delivery use at home among adults with type 1 diabetes mellitus: Results from a 26‐week, free‐living, randomized crossover trial

    Randomized controlled trialTechnology

  15. Diabetes Obes Metab

    Oxidative stress, senescence and mRNA decay in peripheral blood mononuclear cells of women with gestational diabetes mellitus ‐link to increased cardiovascular disease risk

    Mechanistic studyDiabetes in pregnancy

  16. Diabetes Obes Metab

    Trajectories of body mass index and diabetes mellitus risk among elderly Chinese adults: A 10‐year longitudinal study

    Cohort studyT2D & other

  17. Diabetes Obes Metab

    Sustained metabolic improvements in a remotely delivered ketogenic nutrition programme for veterans with type 2 diabetes: A 3‐year observational study

    Cohort studyT2D & other

  18. Diabetes Obes Metab

    Effect of saroglitazar on glycaemic parameters: A systematic review and meta‐analysis of randomized controlled trials

    Meta-analysisT2D & other

  19. Diabetes Obes Metab

    Continuous glucose monitoring‐derived time in range is associated with changes in cognitive function test scores in Japanese patients with type 2 diabetes mellitus

    Cohort studyT2D & other

  20. Diabetes Obes Metab

    Hormonal adaptations to weight loss: Responses to an oral glucose load 4 weeks after obesity surgery and low‐energy diet

    Secondary analysisObesity

  21. Diabetes Obes Metab

    Post‐authorisation safety study to assess the risk of urinary tract cancer in people with type 2 diabetes initiating empagliflozin: A multi‐country European study

    Cohort studyT2D & other

  22. Diabetes Obes Metab

    The effect of sodium‐glucose cotransporter 2 inhibitors on HbA1c variability and cardiovascular and renal adverse outcome in patients with T2DM

    Cohort studyT2D & other

  23. Diabetes Obes Metab

    Incretin‐based therapies for individuals with obesity and heart failure with mildly reduced or preserved ejection fraction: A systematic review and meta‐analysis of randomized controlled trials

    Meta-analysisObesity

  24. Diabetes Obes Metab

    A plasma metabolome‐derived model predicts severe liver outcomes of nonalcoholic fatty liver disease in the UK Biobank

    Diagnostic or prognostic studyLipids & liver

  25. Diabetes Obes Metab

    The interaction of vitamin D supplementation with Omentin‐1 gene polymorphism on metabolic biomarkers, omentin‐1 levels and anthropometric measures in women with prediabetes: A double‐blind randomized controlled trial

    Randomized controlled trialT2D & other

  26. Diabetes Obes Metab

    The use of SGLT2 inhibitors in people with diabetes‐related foot disease: A Delphi‐based consensus study

    Guideline or statementComplications

  27. Diabetes Obes Metab

    Long‐term efficacy of autologous cell therapy, repeated PTA and conservative treatment in people with diabetes and chronic limb‐threatening ischaemia

    Cohort studyComplications

  28. Diabetes Obes Metab

    Association of time in tight range and 1,5‐anhydroglucitol in type 2 diabetes

    Cross-sectional studyT2D & other

  29. Diabetes Obes Metab

    Efficacy and safety of once‐weekly tirzepatide in Japanese participants with type 2 diabetes who have obesity or overweight: Subpopulation analysis of the SURMOUNT ‐2 trial

    Secondary analysisObesity

  30. Diabetes Obes Metab

    Association between weight‐adjusted‐waist index and incident carotid atherosclerosis in the general adult population in Chinese communities: Evidence from the REACTION cohort study

    Cohort study

  31. Diabetes Obes Metab

    Association between estimated glucose disposal rate and lower extremity arterial disease in type 2 diabetes: A nationwide cross‐sectional study from China

    Cross-sectional studyComplications

  32. Diabetes Obes Metab

    Safety, pharmacokinetics and pharmacodynamics of Efsubaglutide Alfa in healthy participants: A randomised, dose‐escalation phase 1 study

    Randomized controlled trialT2D & other

  33. Diabetes Obes Metab

    Genetic risk and polygenic risk score assessment of prediabetes and progression to type 2 diabetes

    Diagnostic or prognostic studyT2D & other

  34. Diabetes Obes Metab

    A1c versus oral glucose tolerance test for chronic glycemic surveillance in women with previous gestational diabetes

    Cohort studyDiabetes in pregnancy

  35. Diabetes Obes Metab

    Haemoglobin glycation index and in‐hospital mortality after acute myocardial infarction in patients with/without diabetes: A prospective, nationwide and multicentre registry

    Cohort studyT2D & other

  36. Diabetes Obes Metab

    Long‐term cost‐effectiveness of tirzepatide for individuals with type 2 diabetes and comorbid obesity

    Research articleT2D & other

  37. Diabetes Obes Metab

    Management of metabolic dysfunction–associated steatotic liver disease ( MASLD )—An expert consensus statement from Indian diabetologists' perspective

    Guideline or statementLipids & liver

  38. Diabetes Obes Metab

    Burden of type 2 diabetes mellitus and risk factor attribution among older adults: A global, regional, and national analysis from 1990 to 2021, with projections up to 2040

    Secondary analysisT2D & other

  39. Diabetes Obes Metab

    Effects of dapagliflozin on sodium excretion, blood pressure and volume status in patients with type 2 diabetes and/or chronic kidney disease: The DAPASALT trial

    Mechanistic studyT2D & other

  40. Diabetes Obes Metab

    Plasma proprotein convertase subtilisin/kexin type 9 ( PCSK9 ) and the risk of chronic kidney disease progression in patients with type 2 diabetes

    Cohort studyComplications

All 2,200 Briefs in ExploreShowing Briefs 1,041–1,080 of 2,200, newest first